Literature DB >> 34793374

Postacute/Long COVID in Pediatrics: Development of a Multidisciplinary Rehabilitation Clinic and Preliminary Case Series.

Amanda K Morrow1, Rowena Ng, Gray Vargas, Dasal Tenzin Jashar, Ellen Henning, Nika Stinson, Laura A Malone.   

Abstract

ABSTRACT: The long-term sequelae after SARS-CoV-2 infections in children is unknown. Guidance is needed on helpful models of care for an emerging subset of pediatric patients with postacute/long COVID who continue to experience persistent symptoms after initial COVID-19 diagnosis. Here, we describe a pediatric multidisciplinary post-COVID-19 rehabilitation clinic model as well as a case series of the initial cohort of patients who presented to this clinic. A consecutive sample of nine patients (pediatric patients <21 yrs of age) who presented to our clinic are included. The most common presenting symptoms were fatigue (8 of 9 patients), headaches (6 of 9), difficulty with schoolwork (6 of 8), "brain fog" (4 of 9), and dizziness/lightheadedness (4 of 9). Most patients had decreased scores on self-reported quality-of-life measures compared with healthy controls. In the patients who participated in neuropsychological testing, a subset demonstrated difficulties with sustained auditory attention and divided attention; however, most of these patients had preexisting attention and/or mood concerns. There were also some who self-reported elevated depression and anxiety symptoms. Pediatric patients with postacute/long COVID may present with a variety of physical, cognitive, and mood symptoms. We present a model of care to address these symptoms through a multidisciplinary rehabilitation approach.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34793374      PMCID: PMC8594395          DOI: 10.1097/PHM.0000000000001896

Source DB:  PubMed          Journal:  Am J Phys Med Rehabil        ISSN: 0894-9115            Impact factor:   2.159


The COVID-19 pandemic has affected more than 184 million people worldwide, causing almost 4 million deaths. Reports from the American Academy of Pediatrics and Children’s Hospital Association state that there are more than 4 million pediatric cases of COVID-19, representing approximately 14.2% of the cases in the United States.[1] These pediatric cases result in hospitalization rates between 0.1% and 1.9% and death in up to 0.03%.[1] Although children with SARS-CoV-2 are typically asymptomatic or present with mild symptoms acutely,[2] there are subpopulations with higher risk of severe presentations.[3] Most publications in the literature that describe pediatric patients focus on acute manifestations of the SARS-CoV-2 infection and hospitalization considerations,[3-10] such as multisystem inflammatory syndrome (MIS-C) or pediatric inflammatory multisystem syndrome.[11-15] As we learn more about the sequela of SARS-CoV-2 infections, evidence is growing that a cohort of patients continue to have persistent symptoms long after their acute presentations. These patients have been termed “long-haulers” or diagnosed with “long-COVID” or “postacute COVID syndrome.”[16-21] Some of the symptoms of postacute/long COVID in adults include fatigue, muscle weakness, shortness of breath, sleep difficulties, anxiety, and depression. Most articles describe these symptoms in adults that were hospitalized during their acute infection,[22-24] but we know that hospitalization rates among children with SARS-CoV-2 infection remain low, which may lead to an underrecognition of this syndrome for pediatric patients. A recent survey study found that 42.6% of pediatric patients experienced at least one persistent symptom more than 60 days from initial infection despite only 4.7% of the patients having been hospitalized.[25] Postacute/long COVID may be a significant concern in the pediatric population even in patients who do not require hospitalization.[25,26] The pathophysiology underlying the symptoms of postacute/long COVID is not yet understood, nor do we know whether certain risk factors predispose children or adults to these syndromes. Given the varied presentations and symptoms, it is possible that postacute/long COVID is multifactorial in nature. As a result of this need, we have developed a multidisciplinary Pediatric Post COVID-19 Rehabilitation Clinic at the Kennedy Krieger Institute to serve pediatric patients with persistent symptoms after initial COVID-19 infection. Here, we describe the structure of this clinic and clinical approach to this patient population and share a case series of an initial cohort of patients.

CLINIC STRUCTURE

The Post COVID-19 Rehabilitation Clinic provides a multidisciplinary rehabilitation approach that addresses medical, psychosocial, and cognitive concerns with a goal to improve patients’ overall functioning to better participate in day-to-day tasks, physical activity, and schooling. Specific symptoms are addressed in the context of additional psychosocial and environmental factors that may affect overall quality of life. The multidisciplinary team consists of medicine (neurology and pediatric rehabilitation medicine), physical therapy, behavioral psychology, neuropsychology, and social work. Assessments are performed in an outpatient clinical setting, and cases are discussed among team members to provide comprehensive recommendations.

Medical

The medical assessment includes evaluations by neurology and pediatric rehabilitation medicine. History and physical examinations are performed including a full neurologic examination and a mobility evaluation. A 10-min standing tolerance test is performed to evaluate for orthostatic intolerance (OI).[27] Information is collected including timing and characterization of initial diagnosis of COVID-19, previous diagnostic workup and treatments, and persistent symptoms. Physicians provide therapeutic recommendations to address specific symptoms while considering how symptoms may be interconnected as part of the postacute/long COVID syndrome. If there are any concerning signs or symptoms that warrant further evaluation, additional diagnostic workup and/or referral to appropriate medical subspecialists is made.

Physical Therapy

Because many patients complain of fatigue and difficulty with physical activity, a formal evaluation is performed by a licensed physical therapist to target therapeutic exercise interventions specific to each patient. Each evaluation includes an assessment for baseline strength using manual muscle testing, range of motion, balance using functional balance grades, and observation of functional mobility and gait. Physical performance and functional capacity are measured using the following measures[28]: time to ascend/descend stairs,[29] 2-min walk test,[30-32] and 30-sec sit to stand.[33]

Behavioral Psychology/Social Work

Given the potential impact of changes in physical symptoms on daily functioning and emotional well-being, a licensed psychologist with specialization in pediatric psychology and a licensed clinical social worker meet with patients and families to support patient and family coping. The social worker discusses family well-being and functioning to ascertain whether additional family support and/or resources could be useful. The psychologist uses a biopsychosocial framework[34] for assessment and intervention, which recognizes the multiple biological, psychological, and social aspects that contribute to the experience of illness. Assessment includes a clinical interview of functioning across a variety of domains including adjustment to medical changes, health-related behaviors (e.g., sleep, appetite, hydration, physical activity), physical symptom management, premorbid mental health concerns, behavioral concerns, and school concerns. In addition to structured measures of mood, anxiety, and quality of life, additional assessment considerations include measures of functional disability (e.g., Functional Disability Inventory[35]) and caregiver perspectives of patients’ quality of life (e.g., Pediatric Quality of Life [PedsQL] Inventory–Parent Proxy Report[36]). Consistent with the role of pediatric psychologists in multidisciplinary hospital-based clinics, information is shared with the clinic team to inform broader team recommendations.[37,38] Brief targeted intervention is also provided in clinic including psychoeducation about relevant topics, facilitation of problem solving, and brief cognitive-behavioral or other therapeutic techniques. Interventions are individualized and based on presenting concern. Referrals for ongoing outpatient or more intensive services are also provided as warranted.

Neuropsychology

As part of a multidisciplinary rehabilitation service model, neuropsychological consultation plays an essential role in facilitating treatment and educational planning. A neuropsychological screening protocol was developed to provide a brief assessment of cognitive domains thought to potentially be affected by COVID-19. This was based on previous studies of adults with postacute/long COVID and patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and concussion/mild traumatic brain injury.[39] Our test battery was designed for implementation for either in-person or telehealth (audio-video) visits to accommodate families seeking clinical services from out of town. As suggested by the growing demand for telehealth services,[40] a flexible model of neuropsychological care is considered necessary during this medical crisis. Behavioral screeners were included to determine the need for more in-depth characterization of externalizing/internalizing symptoms. This protocol is administered by neuropsychologists or psychology associates supervised by neuropsychologists. Based on the patient’s developmental functioning, presenting concerns, sensory/motor deficits, and behavioral compliance, alternative or additional cognitive measures may be given.

METHODS

Cohort

Detailed in this case series are the first nine patients that presented to our multidisciplinary Pediatric Post COVID-19 Rehabilitation Clinic at the Kennedy Krieger Institute in Baltimore, Maryland. This retrospective medical record review case series was acknowledged by the Johns Hopkins Medicine Institutional Review Board as exempt research. All patients or guardians provided informed written consent for publication of their case. The cohort included patients younger than 21 yrs who were either local or traveled from other states within the United States. Patients were self-referred. Patients were screened by the clinic directors for a history of SARS-CoV-2 infection. They either had a history of a positive COVID-19 test (nucleic acid test [NAT] or serum antibody test) or an acute clinical presentation consistent with COVID-19. Most of the clinical diagnoses also had a known close exposure to COVID-19 before symptom onset. Patients with a clinical diagnosis were included given limited testing availability in the early phases of the pandemic, especially for those with mild symptoms. Initial evaluations were done via an in-person visit with neuropsychological evaluations (in-person or telehealth) completed within a week after the clinic visit based on the family’s availability. Given the elevated reports of severe fatigue, this assessment was scheduled on a separate day to avoid overexerting patients with the multiple clinical visits and tests. Formal statistical tests were not completed because of the small sample size. Information presented is meant to be descriptive in nature.

Assessments

Pediatric quality-of-life assessments were completed by the patients on the day of the initial visit. The PedsQL Version 4.0 Generic Short Form is composed of 15 items across 4 dimensions: physical functioning, emotional functioning, social functioning, and school functioning. In addition to a total score, there are two summary scores: physical, composed of the physical functioning items, and psychosocial, composed of the emotional, social, and school items. The PedsQL Multidimensional Fatigue Scale is composed of 18 items across three dimensions: general fatigue, sleep/rest fatigue, and cognitive fatigue. The Multidimensional Fatigue Scale is reported as total and the three subscale scores. Published normative values from healthy children for the Generic PedsQL Inventory[41] and Multidimensional Fatigue PedsQL Inventory[42] were used for comparison. In past studies, the PedsQL has demonstrated internal consistency, construct validity, and discriminant validity.[41-44] The standing tolerance test was completed on the day of the initial visit in the same methodology as described by Roma et al.[27] (2018), which is a modification of the passive standing test of Hyatt et al.[45] Briefly, an automated blood pressure cuff (Dynamap) was placed on the right upper limb, recording blood pressure and heart rate (HR) at 1-min intervals throughout the test. As blood pressure and HR were recorded every minute, the patient was also asked about the severity of orthostatic symptoms on a 0- to 10-point scale. The standing tolerance test was stopped early at the request of the patient or in the event of severe presyncope. Table 1 details the recommended neuropsychological screening battery as a function of patient’s age. Importantly, a semiflexible battery approach was adopted across cases.
TABLE 1

Outpatient neuropsychological screening protocol applied through traditional in-person and novel telehealth assessment models

Cognitive Constructs3–4 yrs5–7 yrs8–15 yrs16–17 yrs18+ yrs
Verbal skillsDAS-II Naming VocabularyDAS-II Naming Vocabulary (5–6 yrs) or WASI-II Vocabulary (6+ yrs)WASI-II VocabularyWASI-II VocabularyWASI-II Vocabulary
Nonverbal reasoningDAS-II MatricesDAS-II Matrices (5–6 yrs) or WASI-II Matrix Reasoning (6+ yrs)WASI-II Matrix ReasoningWASI-II Matrix ReasoningWASI-II Matrix Reasoning
Working memoryDAS-II: Digits ForwardDAS-II: Digits ForwardWISC-V: Digit SpanWAIS-IV Digit SpanWAIS-IV Digit Span
AttentionTEA-Ch Score (6+ yrs)TEA-Ch Score and Score DTCMS Sequences (16 yrs), BTA (17 yrs)TEA Elevator Counting and Elevator Counting With Distractions
Processing speedNEPSY-II Inhibition–NamingOral SDMTOral SDMTOral SDMT
Executive functionNEPSY-II Inhibition and SwitchingDKEFS Verbal FluencyDKEFS Verbal FluencyDKEFS Verbal Fluency
Verbal memoryChAMP ListChAMP ListChAMP ListCVLT-3
Performance validity indicatorMVP VerbalMVP VerbalMVP VerbalMVP Verbal

ADHD-RS-V, ADHD Rating Scale; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; BASC-3, Behavior Assessment System for Children, Third Edition; BRIEF-A, Behavior Rating Inventory of Executive Function Adult; BRIEF-P, Behavior Rating Inventory of Executive Function Preschool; BRIEF-2, Behavior Rating Inventory of Executive Function 2nd Edition; BTA, Brief Test of Attention; CVLT-3, California Verbal Learning Test, Third Edition; ChAMP, Child and Adolescent Memory Profile; CDI-2, Children’s Depression Inventory, Second Edition; CMS, Children’s Memory Scale; CAARS, Conners Adult ADHD Rating Scales; CBRS, Conners Behavior Rating Scale; DKEFS, Delis Kaplan Executive Function System; DAS-II, Differential Abilities Scale, Second Edition; NEPSY-II, Developmental Neuropsychological Assessment; MVP, Memory Validity Profile; MASC-2, Multidimensional Anxiety Scale for Children, Second Edition; RCADS, Revised Children’s Anxiety and Depression Scale; RCMAS-2, Revised Children’s Manifest Anxiety Scale, Second Edition; SDMT, Symbol Digits Modalities Test; TEA-Ch, Test of Everyday Attention for Children; VBRS ODD/CD, Vanderbilt Behavior Rating Scale Oppositional Defiant and Conduct Problems; WASI-II, Wechsler Abbreviated Scale of Intelligence, Second Edition; WAIS-IV, Wechsler Adult Intelligence Scale, Fourth Edition; WISC-V, Wechsler Intelligence Scale for Children, Fifth Edition.

Outpatient neuropsychological screening protocol applied through traditional in-person and novel telehealth assessment models ADHD-RS-V, ADHD Rating Scale; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; BASC-3, Behavior Assessment System for Children, Third Edition; BRIEF-A, Behavior Rating Inventory of Executive Function Adult; BRIEF-P, Behavior Rating Inventory of Executive Function Preschool; BRIEF-2, Behavior Rating Inventory of Executive Function 2nd Edition; BTA, Brief Test of Attention; CVLT-3, California Verbal Learning Test, Third Edition; ChAMP, Child and Adolescent Memory Profile; CDI-2, Children’s Depression Inventory, Second Edition; CMS, Children’s Memory Scale; CAARS, Conners Adult ADHD Rating Scales; CBRS, Conners Behavior Rating Scale; DKEFS, Delis Kaplan Executive Function System; DAS-II, Differential Abilities Scale, Second Edition; NEPSY-II, Developmental Neuropsychological Assessment; MVP, Memory Validity Profile; MASC-2, Multidimensional Anxiety Scale for Children, Second Edition; RCADS, Revised Children’s Anxiety and Depression Scale; RCMAS-2, Revised Children’s Manifest Anxiety Scale, Second Edition; SDMT, Symbol Digits Modalities Test; TEA-Ch, Test of Everyday Attention for Children; VBRS ODD/CD, Vanderbilt Behavior Rating Scale Oppositional Defiant and Conduct Problems; WASI-II, Wechsler Abbreviated Scale of Intelligence, Second Edition; WAIS-IV, Wechsler Adult Intelligence Scale, Fourth Edition; WISC-V, Wechsler Intelligence Scale for Children, Fifth Edition.

RESULTS

Table 2 reports demographic information and symptoms for patients in our clinic. Our patients varied in age between 4 and 18 yrs, with 6 of 9 patients being adolescents. Only one patient was hospitalized during the acute illness and was diagnosed with MIS-C. He is the youngest patient presented here, and his symptoms had mostly resolved by the time when he was seen in our clinic. The remainder of the patients were children and adolescents in the community with relatively mild acute illnesses who developed persistent symptoms after their acute COVID-19 infection. We ascertained patients’ primary complaints through an intake questionnaire and clinical interview on the initial visit where patients/parents described symptoms in their own words (Table 2). Postacute/long COVID symptoms were varied, but we saw most patients complaining of fatigue (8 of 9) and headaches (6 of 9). Patients also described cognitive difficulties or “brain fog” (4 of 9), school concerns (6 of 8), and dizziness/lightheadedness (4 of 9). Only three patients reported cardiopulmonary complaints as one of their postacute symptoms or most important concern at the visit; however, on review of systems, a majority of our patients (5 of 9) did have at least one persistent cardiopulmonary symptom at the time of initial clinic visit. Reported symptoms included chest pain/pressure/tightness (4/5), palpitations (2/5), and shortness of breath (4/5). Of the five patients with persistent symptoms, workup by other providers before presentation in our clinic included electrocardiogram (3 of 5), chest radiograph (4 of 5), echocardiogram (1 of 5), cardiac enzymes (1 of 5), Holter monitor (1 of 5), cardiac stress test (1 of 5), pulmonary function test (1 of 5), and peak flow meter (1 of 5). All testing was reportedly normal with the exception of one patient with peak flow meter measurement who had an improvement in peak flow after bronchodilator use. Of note, these five patients did not include the one patient with a history of MIS-C (patient 3) as this patient had complete resolution of all cardiopulmonary symptoms at the time of our clinic evaluation. Patient 3 did have previous abnormal chest imaging and echocardiograms related to his MIS-C diagnosis.
TABLE 2

Patient characteristics

Patient NumberAgeSexPreexisting ConditionsCOVID-19 Diagnosis DetailsAcute HospitalizationTime Since COVID-19 DiagnosisPostacute SymptomsMost Important ConcernSchool Concerns
118 yrsFType 1 diabetes, anxiety, depressionClinical diagnosis with known exposureN8 mosFatigue, muscle weakness, dizziness, headaches, difficulty concentrating, OI, nonepileptic seizuresNonepileptic seizuresN
212 yrsFNoneClinical diagnosis with known exposureN2 mosPanic attacks, trouble focusing and prioritizing (“brain fog”), abnormal movements, fatigue“Brain fog” and mental healthY
34 yrsMSpeech delayCOVID-19 NAT+Y (MIS-C)4 mosNoneDevelopmental delays and spells concerning for seizureN/A
415 yrsFAnxiety, asthma, seasonal allergiesCOVID-19 NAT+N7 mosTrouble breathing, dizziness, fatigue, lung pain, parosmia, anxietyMental health/anxietyY
517 yrsFDyslexia, seasonal allergiesClinical diagnosisN11 mosBrain fog, functional neurological disorder, headaches, fatigue, cognitive issues, pain, deconditioning, OIAutonomic dysfunctionY
615 yrsFNoneCOVID-19 NAT+N7 mosFatigue, shortness of breath, headaches, OIFatigue and shortness of breathY
79 yrsMEosinophilic esophagitis, speech delay (resolved)Clinical diagnosis with known exposureN11 mosHeadaches, fatigue, anxiety, sensory issues, “brain fog,” lymphadenopathyHeadaches and “brain fog”Y
813 yrsFSensory processing disorder, vitiligo, fructose malabsorption, scoliosisCOVID-19 antibody+N12 mosAbdominal pain, fatigue, myalgias, headaches, facial flushing, rashes/hivesAbdominal painN
99 yrsMMigraine, multiple concussions, sensory integration disorderCOVID-19 NAT+N3 mosHeadaches, chest pain/tightness, fatigue, diarrhea, sore throat, swollen glands, deconditioningChest tightness/painY

Patient demographic information and details on the acute COVID-19 diagnosis and illness along with presenting symptoms are described. If patients reported declining school performance (e.g., grades) and/or difficulty completing schoolwork, they are described as having school concerns in the table. Note that only one patient described was hospitalized with MIS-C, and this child had no postacute concerns but rather an evaluation was completed for preexisting developmental delays. He was also the youngest patient seen in clinic and therefore some more subtle complaints may have been missed.

N/A, not applicable; N, no; Y, yes.

Patient characteristics Patient demographic information and details on the acute COVID-19 diagnosis and illness along with presenting symptoms are described. If patients reported declining school performance (e.g., grades) and/or difficulty completing schoolwork, they are described as having school concerns in the table. Note that only one patient described was hospitalized with MIS-C, and this child had no postacute concerns but rather an evaluation was completed for preexisting developmental delays. He was also the youngest patient seen in clinic and therefore some more subtle complaints may have been missed. N/A, not applicable; N, no; Y, yes. We report testing and questionnaire results from the patients in Table 3. The standing tolerance test results are reported as symptom progression and HR changes from supine to standing to screen for postural orthostatic tachycardia syndrome (POTS). Criteria for a diagnosis of POTS for patients younger than 20 yrs requires worsening of orthostatic symptoms and a HR increase of ≥40 beats per minute (bpm) or an upright HR of at least 120 bpm,[27] although more recent studies have recommended using an HR increase of ≥30 bpm as a cutoff.[46] Six of seven of our patients who completed the standing tolerance test experienced symptoms and >30 bpm change in HR with two of the patients with a >40-bpm change. Any patient that was close to meeting the diagnostic criteria was referred to a POTS specialist for diagnosis and management. In addition, we assessed how the constellation of symptoms children were experiencing affected their quality of life. We found that most patients reported substantial impact on their quality of life, as assessed by the self-report PedsQL Core and Fatigue questionnaires (Table 3). Healthy control published data are reported for comparison on the self-report core scale (n = 5480)[41] and fatigue scale (n = 52).[42]
TABLE 3

Results of standing tolerance test and PedsQL self-report questionnaires

Patient NumberStanding Tolerance Test (Changes Reported From Supine to Standing)PedsQL CorePedsQL Fatigue
TotalPhysical SubscalePsychosocial SubscaleTotalGeneral SubscaleSleep/Rest SubscaleCognitive Subscale
1Worse symptoms (dizziness) HR increase 36 bpm51.121.966.72520.816.737.5
2Worse symptoms (headache and dizziness)HR increase 35 bpm58.756.36056.95070.850
3
4Worse symptoms (dizziness and fatigue) HR increase 33 bpm48.931.358.336.137.54.266.7
5N/A previously diagnosed with POTS via tilt-table test18.5028.326.44.241.733.3
6Worse symptoms (weakness and headache) HR increase 51 bpm55.443.861.743.133.32570.8
7Worse symptoms (dizziness, headache, fatigue, blurry vision) HR increase 32 bpm
8Stable symptoms HR increase 29 bpm85.981.388.388.991.795.879.2
9Worse symptoms (headache and fatigue) HR increase 44 bpm52.231.363.3
Healthy subjects (published data[41,42])83.8 ± 12.787.5 ± 13.581.9 ± 14.180.5 ± 13.385.3 ± 1575 ± 18.881.1 ± 17.4

The norms for healthy subjects from published data are reported for the PedsQL questionnaires for comparison. For analysis, items are reverse scored and linearly transformed to a 0- to 100- point scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, and 4 = 0). Higher values on the PedsQL represent better health-related quality of life. Of note, patient 3 was too young to complete the self-report questionnaire. Because of a clerical error, patient 7 did not receive questionnaires to fill out during initial evaluation and patient 9 only received one of the questionnaires for which there are missing data.

Results of standing tolerance test and PedsQL self-report questionnaires The norms for healthy subjects from published data are reported for the PedsQL questionnaires for comparison. For analysis, items are reverse scored and linearly transformed to a 0- to 100- point scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, and 4 = 0). Higher values on the PedsQL represent better health-related quality of life. Of note, patient 3 was too young to complete the self-report questionnaire. Because of a clerical error, patient 7 did not receive questionnaires to fill out during initial evaluation and patient 9 only received one of the questionnaires for which there are missing data. Table 4 provides an overview of the testing results for the neuropsychological evaluations. Of note, one patient could not complete testing because of scheduling difficulties and interstate telepsychological practice regulations. The neuropsychological screening battery was not administered to two of the remaining eight patients referred for testing because of difficulty engaging in testing or developmental level. Testing was discontinued for one patient shortly after the session began because of significant anxiety and mood regulation difficulties. Most patients who participated in neuropsychological testing presented with intact verbal ability, visual reasoning, executive functioning (including working memory), processing speed, and verbal memory. Half or more of these patients exhibited difficulties with sustained auditory attention and divided attention, and many had elevated parent and self-report of inattention and psychiatric symptoms. However, it is important to note that the majority of these patients had preexisting attention, mood, and/or anxiety concerns. Therefore, the impairments observed on testing and symptoms reported on rating scales cannot be directly attributed to the long-term effects of COVID-19 alone. These results are currently presented qualitatively because of sample size. It is expected that a larger sample size will be established in the future as additional patients are evaluated, which will allow for quantitative analysis.
TABLE 4

Neuropsychological and psychosocial functioning of initial clinical cohort evaluated through the pediatric post–COVID-19 rehabilitation clinic

Cognitive DomainPatients With Impaired Performance
Verbal skills0 of 4
Nonverbal reasoning0 of 4
Working memory0 of 5
Attention
 Sustained auditory attention3 of 5
 Divided attention2 of 4
Processing speed0 of 5
Executive functioning0 of 5
Verbal memory0 of 5
Validity0 of 5

Impairment on performance-based cognitive measures are defined as scaled score <6, standard score <80, t score <37, z score <−1.33, or percentile <9th. Elevated symptoms on caregiver- or self-report inventories are defined as t score >65. Pre–COVID-19 behavioral and cognitive concerns represent areas of difficulty that patients displayed before the viral infection, based on caregiver and/or self-report.

Neurodevelopmental concerns include developmental delays. Two reported speech/language delays and one reported motor delays paired with early sensory processing concerns.

CBRS, Conners Behavior Rating Scale; CDI-2, Children’s Depression Inventory, Second Edition; MASC-2, Multidimensional Anxiety Scale for Children, Second Edition.

Neuropsychological and psychosocial functioning of initial clinical cohort evaluated through the pediatric post–COVID-19 rehabilitation clinic Impairment on performance-based cognitive measures are defined as scaled score <6, standard score <80, t score <37, z score <−1.33, or percentile <9th. Elevated symptoms on caregiver- or self-report inventories are defined as t score >65. Pre–COVID-19 behavioral and cognitive concerns represent areas of difficulty that patients displayed before the viral infection, based on caregiver and/or self-report. Neurodevelopmental concerns include developmental delays. Two reported speech/language delays and one reported motor delays paired with early sensory processing concerns. CBRS, Conners Behavior Rating Scale; CDI-2, Children’s Depression Inventory, Second Edition; MASC-2, Multidimensional Anxiety Scale for Children, Second Edition.

DISCUSSION

Here, we describe the multidisciplinary clinic structure, presenting symptoms and concerns, and preliminary results from standardized assessments from patients and families in our Pediatric Post COVID-19 Rehabilitation Clinic at the Kennedy Krieger Institute. We are finding that there is a subset of pediatric patients with mild acute COVID-19 illness that present with persistent or exacerbated symptoms after their acute illness. Our small case series demonstrates that patient symptoms are varied but many complain of fatigue, headaches, cognitive difficulties, and OI. On neuropsychological testing, patients are demonstrating impaired performance primarily with attention as opposed to other domains, such as executive functioning or working memory, which has been reported in the adult literature.[39,47] Elevated anxiety and depression symptoms are also commonly reported. It is also important to note that many of the patients in our cohort had a history of attention and/or mood concerns, although none of the patients reported taking medications to address these concerns before their COVID-19 diagnosis. Therefore, it is possible that these anxiety, attention, and/or mood concerns are not directly related to disease mechanisms associated with COVID-19. Furthermore, the stressors related to COVID-19, such as isolation and virtual schooling, could also have triggered or exacerbated mood and anxiety concerns. In addition, for some, we have found that the reported postacute/long COVID symptoms are significantly affecting their quality of life. There are minimal to no data on how to optimally treat postacute/long COVID in children. Our management strategies are based on other chronic conditions with overlapping symptoms, including ME/CFS, OI/POTS, and concussion/mild traumatic brain injury. We consider medical, physical, behavioral, environmental, and educational interventions that may be helpful. Below are examples of our approach to some of the most common complaints seen in our clinic.

Fatigue

Causes of fatigue are multifactorial and other known medical causes of fatigue are considered. Timing and characterization of fatigue are determined as patients with ME/CFS often describe fatigue as disabling, worse after physical activity, and not improved with sleep.[48] Sleep disturbances are addressed through environmental and behavioral interventions to improve sleep hygiene. Additional treatment options to improve fatigue are discussed including cognitive behavioral therapy and graded exercise therapy, which have been studied in patients with ME/CFS.[49] Subsymptom threshold aerobic exercise has also been shown to be beneficial in patients with persistent symptoms after concussion/mild traumatic brain injury.[50]

Orthostatic Intolerance

Orthostatic intolerance is an abnormal autonomic response with symptoms developing in an upright posture that improve in the supine position.[51] In patients with complaints of dizziness or lightheadedness or who experience symptoms with the standing tolerance test consistent with OI or POTS, initial recommendations include increasing dietary intake of fluids and salt, compression garments, physical countermeasure maneuvers such as leg crossing and muscle pumping, and exercise training with the goal of expanding blood volume.[51,52] A daily routine including maintaining a regular sleep schedule and management of stress and/or anxiety is also important.[53] The Levine Protocol[52] and CHOP Modified Dallas Protocol[54] are examples of exercise protocols developed for OI/POTS. They involve starting with horizontal exercise and slowly increasing duration and intensity of exercise while incorporating upright positioning as tolerated.[52] Referrals to outpatient physical therapy may be made to supervise an individualized graded exercise program and help with reconditioning and symptom management.

Headaches

Characterization of headaches is made based on patient history. Additional brain imaging may be performed if there are any abnormal findings on neurologic examination or if there is concern for secondary causes of headache.[55] Lifestyle modifications are recommended including adequate hydration, avoidance of triggers, optimizing sleep patterns, eating regular meals, stress management, and maintaining physical activity,[55,56] which overlap with some of the previously mentioned recommendations for ME/CFS and OI/POTS. If needed, additional pharmacologic management may be recommended including preventative and abortive medications with education to prevent rebound headaches from overuse of abortive agents.[55]

Cognitive Dysfunction

Targeted neuropsychological testing is performed to identify any areas of cognitive weakness, mood, and behavioral factors in need of further evaluation/treatment. Recommendations are given to optimize day-to-day cognitive functioning and school participation and performance and to address mood or behavioral difficulties as necessary. Similar to approaches outlining return to school after concussion/mild traumatic brain injury,[57] our team may recommend a gradual transition back to learning with the potential need for temporary academic adjustments or environmental accommodations if symptoms are exacerbated in the school setting. Examples of adjustments include planned rest breaks, increased test taking time, and/or limiting amount of homework assignments as patients are building up their tolerance for academic activity. If there are concerns for ADHD, appropriate treatment recommendations are made including behavioral therapy and medication management.[58]

Mood/Psychological Symptoms

Patients are screened for comorbid mood and psychological symptoms, which may exacerbate other symptoms and limit recovery potential. Anxiety and depressive symptoms commonly co-occur in patients with ME/CFS,[58] OI/POTS,[53] and concussion.[59] For mood/affective symptoms, initial symptoms are addressed by our psychologist in clinic and patients may be referred for outpatient psychotherapy for additional coping and support as well as psychiatry if needed for medication management of significant mood symptoms.

Limitations

There are several limitations to our study including its retrospective and descriptive nature. Given the small sample size, statistical analyses could not be performed. Patients were self-referred to our clinic, which may have resulted in selection bias. We were unable to estimate the prevalence of developing postacute/long COVID in children after SARS-CoV-2 infection because we only had data available for those presenting to our clinic. Future studies are needed to address this important question. Only one of our patients was hospitalized for initial infection, and at this time, we were unable to draw any conclusions regarding long-term implications for patients with more serious infections requiring hospitalization versus those with mild initial symptoms. We decided to include patients with a clinical diagnosis in this case series given limited testing availability in the early phases of the pandemic, especially for those with mild symptoms. Because we included patients both with a positive COVID-19 test and those with a suspicion of COVID-19 diagnosis based on clinical history, we were unable to confirm that all of the reported symptoms and clinical courses were due exclusively to SARS-CoV-2. There is also missing data for some patients who did not complete questionnaires or fully participate in neuropsychological testing. Future studies with larger sample sizes will hopefully be able to address some of these limitations.

CONCLUSIONS

Children with postacute/long COVID may complain of a variety of physical, cognitive, and mood symptoms that impact their overall quality of life and participation in activities. As active research is being pursued to better understand the etiology and mechanisms of disease, our Pediatric Post COVID-19 Rehabilitation Clinic offers a multidisciplinary approach to patient care as we continue to learn more about this condition. Future studies are needed to better characterize the symptoms, clinical course, and syndrome prognosis in addition to guiding personalized treatment recommendations.
  54 in total

1.  Long-COVID: An evolving problem with an extensive impact.

Authors:  M Mendelson; J Nel; L Blumberg; S A Madhi; M Dryden; W Stevens; F W D Venter
Journal:  S Afr Med J       Date:  2020-11-23

2.  COVID-19 in Children: Initial Characterization of the Pediatric Disease.

Authors:  Andrea T Cruz; Steven L Zeichner
Journal:  Pediatrics       Date:  2020-03-16       Impact factor: 7.124

3.  Long-Haul COVID.

Authors:  Avindra Nath
Journal:  Neurology       Date:  2020-08-11       Impact factor: 9.910

4.  Two-minute walk test performance by adults 18 to 85 years: normative values, reliability, and responsiveness.

Authors:  Richard W Bohannon; Ying-Chih Wang; Richard C Gershon
Journal:  Arch Phys Med Rehabil       Date:  2014-10-25       Impact factor: 3.966

5.  A Core Set of Outcome Measures for Adults With Neurologic Conditions Undergoing Rehabilitation: A CLINICAL PRACTICE GUIDELINE.

Authors:  Jennifer L Moore; Kirsten Potter; Kathleen Blankshain; Sandra L Kaplan; Linda C OʼDwyer; Jane E Sullivan
Journal:  J Neurol Phys Ther       Date:  2018-07       Impact factor: 3.649

Review 6.  Exercise and non-pharmacological treatment of POTS.

Authors:  Qi Fu; Benjamin D Levine
Journal:  Auton Neurosci       Date:  2018-07-04       Impact factor: 3.145

Review 7.  Returning to learning following a concussion.

Authors:  Mark E Halstead; Karen McAvoy; Cynthia D Devore; Rebecca Carl; Michael Lee; Kelsey Logan
Journal:  Pediatrics       Date:  2013-10-27       Impact factor: 7.124

8.  Pediatric long-COVID: An overlooked phenomenon?

Authors:  Caroline L H Brackel; Coen R Lap; Emilie P Buddingh; Marlies A van Houten; Linda J T M van der Sande; Eveline J Langereis; Michiel A G E Bannier; Marielle W H Pijnenburg; Simone Hashimoto; Suzanne W J Terheggen-Lagro
Journal:  Pediatr Pulmonol       Date:  2021-06-08

9.  SARS-CoV-2 (COVID-19): What Do We Know About Children? A Systematic Review.

Authors:  Nisha S Mehta; Oliver T Mytton; Edward W S Mullins; Tom A Fowler; Catherine L Falconer; Orla B Murphy; Claudia Langenberg; Wikum J P Jayatunga; Danielle H Eddy; Jonathan S Nguyen-Van-Tam
Journal:  Clin Infect Dis       Date:  2020-12-03       Impact factor: 9.079

10.  Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2.

Authors:  Elizabeth Whittaker; Alasdair Bamford; Julia Kenny; Myrsini Kaforou; Christine E Jones; Priyen Shah; Padmanabhan Ramnarayan; Alain Fraisse; Owen Miller; Patrick Davies; Filip Kucera; Joe Brierley; Marilyn McDougall; Michael Carter; Adriana Tremoulet; Chisato Shimizu; Jethro Herberg; Jane C Burns; Hermione Lyall; Michael Levin
Journal:  JAMA       Date:  2020-07-21       Impact factor: 157.335

View more
  8 in total

Review 1.  Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Children.

Authors:  Eric J Chow; Janet A Englund
Journal:  Infect Dis Clin North Am       Date:  2022-02-01       Impact factor: 5.905

2.  Neuropsychiatric Disorders in Pediatric Long COVID-19: A Case Series.

Authors:  Rosa Savino; Anna N Polito; Giulia Arcidiacono; Mariacristina Poliseno; Sergio Lo Caputo
Journal:  Brain Sci       Date:  2022-04-19

Review 3.  Long-Term COVID 19 Sequelae in Adolescents: the Overlap with Orthostatic Intolerance and ME/CFS.

Authors:  Amanda K Morrow; Laura A Malone; Christina Kokorelis; Lindsay S Petracek; Ella F Eastin; Katie L Lobner; Luise Neuendorff; Peter C Rowe
Journal:  Curr Pediatr Rep       Date:  2022-03-09

4.  Clinicians need to be careful that they do not confuse mental health issues and long COVID in children and adolescents.

Authors:  Giorgio Cozzi; Federico Marchetti; Egidio Barbi
Journal:  Acta Paediatr       Date:  2022-03-13       Impact factor: 4.056

Review 5.  COVID in Pediatric Age: an opinion paper.

Authors:  T Hernández-Sampelayo; J Gómez-Pavón; J González Del Castillo; M C Martín-Delgado; F J Martín Sánchez; M Martínez-Sellés; J M Molero García; S Moreno Guillén; F J Rodríguez-Artalejo; J Ruiz-Galiana; R Cantón; P De Lucas Ramos; A García-Botella; A García-Lledó; P Calvo Rey; E Bouza
Journal:  Rev Esp Quimioter       Date:  2022-03-15       Impact factor: 2.515

6.  Cognitive Difficulties, Psychological Symptoms, and Long Lasting Somatic Complaints in Adolescents with Previous SARS-CoV-2 Infection: A Telehealth Cross-Sectional Pilot Study.

Authors:  Samuela Tarantino; Sonia Graziano; Chiara Carducci; Rosaria Giampaolo; Teresa Grimaldi Capitello
Journal:  Brain Sci       Date:  2022-07-23

7.  Neurocognitive and Psychosocial Characteristics of Pediatric Patients With Post-Acute/Long-COVID: A Retrospective Clinical Case Series.

Authors:  Rowena Ng; Gray Vargas; Dasal Tenzin Jashar; Amanda Morrow; Laura A Malone
Journal:  Arch Clin Neuropsychol       Date:  2022-07-29       Impact factor: 3.448

Review 8.  Prevalence and clinical presentation of long COVID in children: a systematic review.

Authors:  Roberta Pellegrino; Elena Chiappini; Amelia Licari; Luisa Galli; Gian Luigi Marseglia
Journal:  Eur J Pediatr       Date:  2022-09-15       Impact factor: 3.860

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.